Takeda Pharmaceutical Coの空売り状況は、投資家がTakeda Pharmaceutical Coの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Takeda Pharmaceutical Co (NYSE:TAK) 株価情報, 空売り情報

Takeda Pharmaceutical Co

Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co Ltd

TransAKT Ltd

TAKIGAMI STEEL CONSTRCTN by Takigami Steel Construction Co. Ltd.

Takigami Steel Construction Co Ltd

TAKAMATSU CONSTRUCTION GR by TAKAMATSU CONSTRUCTION GROUP CO LTD

Takamatsu Construction Group Co Ltd

VOLATUS AEROSPACE INC by VOLATUS AEROSPACE INC.

Volatus Aerospace Inc

The board of directors of The Brink's Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCO#NYSE">BCO</a>) today declared a regular quarterly dividend of $0.255 cents per share on the company's common stock, an increase of 5%. The dividend is payable on June 2, 2025, to shareholders of record on May 19, 2025.&nbsp;&nbsp;

News

Dividends

Brink's Increases Quarterly Dividend From $0.24 To $0.255 Per Share

Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.75) by 14.67 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $59.55 million which beat the analyst consensus estimate of $54.65 million by 8.96 percent. This is a 62.72 percent increase over sales of $36.60 million the same period last year.

Earnings

Earnings Beats

SDGR

Schrodinger Q1 Adj. EPS $(0.64) Beats $(0.75) Estimate, Sales $59.55M Beat $54.65M Estimate

Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) affirms FY2025 sales outlook from $345.00 million-$355.00 million to $345.00 million-$355.00 million vs $350.97 million estimate.

Guidance

EOLS

Evolus Affirms FY2025 Sales Guidance of $345.00M-$355.00M vs $350.97M Est

Copa Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>) reported quarterly earnings of $4.28 per share which beat the analyst consensus estimate of $3.77 by 13.53 percent. This is a 2.15 percent increase over earnings of $4.19 per share from the same period last year. The company reported quarterly sales of $899.18 million which beat the analyst consensus estimate of $888.29 million by 1.23 percent. This is a 0.64 percent increase over sales of $893.47 million the same period last year.

Copa Holdings Q1 EPS $4.28 Beats $3.77 Estimate, Sales $899.18M Beat $888.29M Estimate

Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.30 by 63.33 percent. This is a 76.09 percent decrease over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $5.10 billion which missed the analyst consensus estimate of $5.15 billion by 0.97 percent. This is a 5.36 percent decrease over sales of $5.39 billion the same period last year.

Nutrien Q1 EPS $0.11 Misses $0.30 Estimate, Sales $5.10B Miss $5.15B Estimate

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 50 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $59.13 million which missed the analyst consensus estimate of $60.60 million by 2.43 percent. This is a 16.87 percent increase over sales of $50.59 million the same period last year.

Earnings Misses

Viemed Healthcare Q1 EPS $0.06, Inline, Sales $59.13M Miss $60.60M Estimate

Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) sees Q2 sales of $121.000 million-$123.000 million vs $119.66 million analyst estimate.

GRPN

Groupon Sees Q2 Sales $121.000M-$123.000M vs $119.66M Est

Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) affirms FY2025 sales outlook from $493.00 million-$500.00 million to $493.00 million-$500.00 million vs $496.96 million estimate.

Groupon Affirms FY2025 Sales Guidance of $493.00M-$500.00M vs $496.96M Est

Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.14 by 7.14 percent. This is a 31.58 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $247.10 million which beat the analyst consensus estimate of $246.95 million by 0.06 percent. This is a 7.72 percent decrease over sales of $267.77 million the same period last year.

BMBL

Bumble Q1 EPS $0.13 Misses $0.14 Estimate, Sales $247.10M Beat $246.95M Estimate

5N Plus (TSX:<a class="ticker" href="https://www.benzinga.com/stock/VNP#TSX">VNP</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 by 83.33 percent. This is a 266.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $88.89 million which beat the analyst consensus estimate of $73.32 million by 21.23 percent. This is a 36.71 percent increase over sales of $65.02 million the same period last year.

TSX:VNP

5N Plus Q1 EPS $0.11 Beats $0.06 Estimate, Sales $88.89M Beat $73.32M Estimate

Trinseo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSE#NYSE">TSE</a>) reported quarterly losses of $(1.37) per share which met the analyst consensus estimate. This is a 29.38 percent increase over losses of $(1.94) per share from the same period last year. The company reported quarterly sales of $784.80 million which missed the analyst consensus estimate of $912.50 million by 13.99 percent. This is a 13.19 percent decrease over sales of $904.00 million the same period last year.

Trinseo Q1 Adj. EPS $(1.37), Inline, Sales $784.80M Miss $912.50M Estimate

GeoPark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.46 by 45.65 percent. This is a 54.55 percent decrease over earnings of $0.55 per share from the same period last year. The company reported $137.30 million in sales this quarter. This is a 17.98 percent decrease over sales of $167.40 million the same period last year.

GPRK

GeoPark Q1 EPS $0.25 Misses $0.46 Estimate, Sales $137.30M Down From $167.40M YoY

Plaza Retail REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PLZ#TSX">PLZ</a>) reported quarterly earnings of $0.09 per share. This is a 1.12 percent decrease over earnings of $0.09 per share from the same period last year. The company reported $31.14 million in sales this quarter. This is a 5.30 percent increase over sales of $29.57 million the same period last year.

TSX:PLZ

Plaza Retail REIT Q1 FFO $0.09 Down From $0.09 YoY, Sales $31.14M Up From $29.57M YoY

Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. The company reported quarterly sales of $154.14 million which missed the analyst consensus estimate of $160.75 million by 4.11 percent.

ARMN

Aris Mining Q1 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $154.14M Miss $160.75M Estimate

Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.07) by 885.71 percent. The company reported quarterly sales of $1.08 billion which missed the analyst consensus estimate of $1.11 billion by 2.07 percent. This is a 1.36 percent decrease over sales of $1.10 billion the same period last year.

LILA

Liberty Latin America Q1 EPS $(0.69) Misses $(0.07) Estimate, Sales $1.08B Miss $1.11B Estimate

Osisko Gold Royalties Ltd (the "Company" or "Osisko") (OR: TSX &amp; NYSE) is pleased to announce that the Board of Directors has approved a second quarter 2025 dividend of US$0.055 per common share, a 20% increase over the previous quarterly dividend, based on the foreign exchange rate (C$/US$) on the declaration date of the first quarter dividend. The dividend will be paid on July 15, 2025 to shareholders of record as of the close of business on June 30, 2025. This dividend is an "eligible dividend" as defined in the Income Tax Act (Canada).
For shareholders residing in Canada, the Canadian dollar equivalent will be determined based on the daily rate published by the Bank of Canada on June 30, 2025.

Osisko Declares Q2 2025 Dividend Of $0.055, A 20% Increase Increase Over The Previous Quarterly Dividend, Based On The Foreign Exchange Rate

OTC Markets Gr (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OTCM#OTC">OTCM</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.53 by 52.83 percent. This is a 6.58 percent increase over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $29.43 million which beat the analyst consensus estimate of $28.16 million by 4.52 percent. This is a 9.75 percent increase over sales of $26.82 million the same period last year.

OTCM

OTC Markets Gr Q1 Adj. EPS $0.81 Beats $0.53 Estimate, Sales $29.43M Beat $28.16M Estimate

Ring Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REI#AMEX">REI</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 50 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $79.09 million which missed the analyst consensus estimate of $80.67 million by 1.95 percent. This is a 16.31 percent decrease over sales of $94.50 million the same period last year.

Ring Energy Q1 Adj. EPS $0.05 Misses $0.06 Estimate, Sales $79.09M Miss $80.67M Estimate

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 10 years by 4.9% on an annualized basis producing an average annual return of 15.23%. Currently, Stryker has a market capitalization of $146.59 billion. 
Buying $100 In SYK: If an investor had bought $100 of SYK stock 10 years ago, it would be worth $407.02 today based on a price of $384.06 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746653424_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Stryker 10 Years Ago Would Be Worth Today

New Pacific Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NEWP#AMEX">NEWP</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year.

NEWP

New Pacific Metals Q3 EPS $(0.01), Inline

Press Releases

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Comments

Takeda Pharmaceutical Co

空売り

Takeda Pharmaceutical Co (NYSE:TAK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル